Page last updated: 2024-11-10

swerchirin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

swerchirin: from Swertia tetrapetala Pall; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

swerchirin : A member of the class of xanthones that is the 5-O-methyl derivative of bellidifolin. Isolated from Centaurium erythraea and Swertia chirayita, it exhibits hypoglycemic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
SwertiagenusA plant genus of the family GENTIANACEAE. It is a source of swertiapuniside and IRIDOID GLYCOSIDES.[MeSH]GentianaceaeA plant family of the order Gentianales, subclass Asteridae, class Magnoliopsida.[MeSH]
CentauriumgenusA plant genus of the family GENTIANACEAE. Triterpene lactones and other compounds have been isolated from species of this genus. The common name of century plant has also been used for the AGAVE genus.[MeSH]GentianaceaeA plant family of the order Gentianales, subclass Asteridae, class Magnoliopsida.[MeSH]
Swertia chirayitaspecies[no description available]GentianaceaeA plant family of the order Gentianales, subclass Asteridae, class Magnoliopsida.[MeSH]
Centaurium erythraeaspecies[no description available]GentianaceaeA plant family of the order Gentianales, subclass Asteridae, class Magnoliopsida.[MeSH]
Swertia tetrapetalaspecies[no description available]GentianaceaeA plant family of the order Gentianales, subclass Asteridae, class Magnoliopsida.[MeSH]

Cross-References

ID SourceID
PubMed CID5281660
CHEBI ID9368
SCHEMBL ID18240051
MeSH IDM0106001

Synonyms (22)

Synonym
521-65-3
swerchirin
3,5-dimethoxy-1,8-dihydroxyxanthone
5-o-methylbellidifolin
methylbellidifolin
xanthen-9-one, 1,8-dihydroxy-3,5-dimethoxy-
9h-xanthen-9-one, 1,8-dihydroxy-3,5-dimethoxy-
1,8-dihydroxy-3,5-dimethoxyxanthenone
brn 0313581
1,8-dihydroxy-3,5-dimethoxyxanthen-9-one
1,8-dihydroxy-3,5-dimethoxy-9h-xanthen-9-one
qqb9x426dm ,
unii-qqb9x426dm
1,8-dihydroxy-3,5-dimethoxy-xanthenone
CHEBI:9368
1,8-dihydroxy-3,5-dimethoxyxanthone
SCHEMBL18240051
GNSHHHWDGOHNPC-UHFFFAOYSA-N
1,8-dihydroxy-3,5-dimethoxy-xanthen-9-one
DTXSID80200102
Q27089378
AKOS040754119
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
hypoglycemic agentA drug which lowers the blood glucose level.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
xanthonesAny member of the class of xanthenes based on a xanthone skeleton.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (12.50)18.7374
1990's4 (50.00)18.2507
2000's2 (25.00)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]